CLINICAL TRIALS PROFILE FOR OXYTETRACYCLINE

All Clinical Trials for oxytetracycline

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00570648 ↗	A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization	Completed	University of Virginia	N/A	2007-06-01	Hypothesis: 1% sodium hyaluronate (Healon), applied at end of surgery to the surface of a corneal transplant will not shorten graft reepithelialization time when compared to coating with nothing. We also wish to measure and compare visual acuity in this immediate post operative period. We also wish to assess the safety of using this agent on the epithelium post-operatively. We will recruit 50 high risk patients (see inclusion criteria) here at the University of Virginia to randomly receive nothing or sodium hyaluronate (Healon) on the ocular surface at the end of surgery, and follow time to reepithelialization of the corneal transplant grafts.
NCT01032499 ↗	Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir	Unknown status	Laboratorios Goulart S.A.	Phase 3	2010-05-01	To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils or acne.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Clinical Trial Conditions for oxytetracycline

Condition Name

Condition Name for oxytetracycline
Intervention	Trials
Osteomyelitis	1
Post-Operative Wound Infection	1
Acne Vulgaris II or III Degree	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for oxytetracycline
Intervention	Trials
Dry Socket	1
Osteomyelitis	1
Atrial Fibrillation	1
Wound Infection	1

Clinical Trial Locations for oxytetracycline

Trials by Country

Trials by Country for oxytetracycline
Location	Trials
Brazil	3
United States	2
Norway	1

Trials by US State

Trials by US State for oxytetracycline
Location	Trials
Kentucky	1
Virginia	1

Clinical Trial Progress for oxytetracycline

Clinical Trial Phase

Clinical Trial Phase for oxytetracycline
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
N/A	2

Clinical Trial Status

Clinical Trial Status for oxytetracycline
Clinical Trial Phase	Trials
Completed	3
Unknown status	1
Terminated	1

Clinical Trial Sponsors for oxytetracycline

Sponsor Name

Sponsor Name for oxytetracycline
Sponsor	Trials
University of Louisville	1
Julio Ramirez	1
University of Oslo	1

Sponsor Type

Sponsor Type for oxytetracycline
Sponsor	Trials
Other	7
Industry	1